Johnson & Johnson plans to buy the global rights to an experimental eczema therapy for $1.25 billion in cash, the company said May 28.
The therapy is a bispecific antibody about to enter phase 2 studies targeting atopic dermatitis, a common inflammatory skin disease. Pending regulatory approval, J&J expects to acquire the drug candidate from Switzerland-based Numab Therapeutics in the second half of 2024.